Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension
J. Clin. Invest. Ventzislav Petkov, et al. 111:1339 doi:10.1172/JCI17500 [Go to this article.]

Figure 2
VIP serum concentration. VIP serum concentration as determined by RIA of control individuals, pancreatic cancer patients, and PPH patients.